Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. 2019

Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, PR China.

A novel series of acetamide-substituted derivatives and two prodrugs of doravirine were designed and synthesized as potent HIV-1 NNRTIs by employing the structure-based drug design strategy. In MT-4 cell-based assays using the MTT method, it was found that most of the new compounds exhibited moderate to excellent inhibitory potency against the wild-type (WT) HIV-1 strain with a minimum EC50 value of 54.8 nM. Among them, the two most potent compounds 8i (EC50 = 59.5 nM) and 8k (EC50 = 54.8 nM) displayed robust activity against WT HIV-1 with double-digit nanomolar EC50 values, being superior to lamivudine (3TC, EC50 = 12.8 μM) and comparable to doravirine (EC50 = 13 nM). Besides, 8i and 8k shown moderate activity against the double RT mutant (K103N + Y181C) HIV-1 RES056 strain. The HIV-1 RT inhibition assay further validated the binding target. Molecular simulation of the representative compounds was employed to provide insight on their structure-activity relationships (SARs) and direct future design efforts. Finally, the aqueous solubility and chemical stability of the prodrugs 9 and 10 were investigated in detail.

UI MeSH Term Description Entries
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
June 2021, Bioorganic & medicinal chemistry,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
January 2015, Bioorganic & medicinal chemistry,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
November 2023, European journal of medicinal chemistry,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
November 2017, European journal of medicinal chemistry,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
December 2013, Bioorganic & medicinal chemistry,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
December 2012, Bioorganic & medicinal chemistry letters,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
June 2014, Organic & biomolecular chemistry,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
November 2009, Bioorganic & medicinal chemistry,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
April 2013, Bioorganic & medicinal chemistry,
Zhao Wang, and Zhao Yu, and Dongwei Kang, and Jian Zhang, and Ye Tian, and Dirk Daelemans, and Erik De Clercq, and Christophe Pannecouque, and Peng Zhan, and Xinyong Liu
December 2011, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!